Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
暂无分享,去创建一个
W. Stock | K. Schmiegelow | R. Tuckuviene | O. Nielsen | T. Frandsen | B. Als-Nielsen | N. Toft | C. U. Rank | L. S. Lynggaard
[1] A. Tong,et al. Evaluation of the Cochrane Consumers and Communication Group’s systematic review priority-setting project , 2020, Health Research Policy and Systems.
[2] Shannon R. McCurdy,et al. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation , 2020, Leukemia & lymphoma.
[3] M. Minden,et al. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase‐based therapy , 2020, British journal of haematology.
[4] L. Michaelis,et al. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study. , 2020, Leukemia research.
[5] H. Dombret,et al. Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study. , 2020, Blood.
[6] M. Cushman,et al. DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. , 2020, Blood advances.
[7] M. Carrier,et al. Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches? , 2020, Thrombosis research.
[8] C. Flowers,et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. DeAngelo,et al. The prevention and management of asparaginase‐related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH , 2020, Journal of thrombosis and haemostasis : JTH.
[10] A. Tang,et al. Risk factors for venous thromboembolism in hospitalized patients with hematological malignancy: an analysis of the National Inpatient Sample, 2011–2015 , 2019, Leukemia & lymphoma.
[11] M. Nomdedeu,et al. Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies , 2020, Leukemia & lymphoma.
[12] Zongan Liang,et al. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer , 2020, Hematology.
[13] M. Minden,et al. Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib , 2019, Blood.
[14] Anne-Céline Martin,et al. Specific Antidotes for Direct Oral Anticoagulant Reversal: Case Closed or Cold Case? , 2019, Circulation.
[15] L. Brandão,et al. Effectiveness and Safety of Primary Thromboprophylaxis in Children with Cancer: A Systematic Review of the Literature and Network Meta-Analysis , 2019, Thrombosis and Haemostasis.
[16] J. Douketis,et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. , 2019, The Lancet. Oncology.
[17] W. Stock,et al. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia , 2019, Cochrane Database of Systematic Reviews.
[18] Natalie S Blencowe,et al. RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.
[19] A. Khorana,et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH , 2019, Journal of thrombosis and haemostasis : JTH.
[20] I. Aurer,et al. PB1669 RISK FACTORS FOR THROMBOEMBOLISM IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA , 2019, HemaSphere.
[21] G. Behbehani,et al. Incidence, characteristics, and risk factors of venous thromboembolism in adolescent and young adult acute lymphoblastic leukemia patients receiving peg-asparaginase. , 2019, Journal of Clinical Oncology.
[22] C. Bloomfield,et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. , 2019, Blood.
[23] S. O’Brien,et al. THROMBOTECT takes the lead , 2019, Haematologica.
[24] P. Wells,et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer , 2019, The New England journal of medicine.
[25] Cassini Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. , 2019 .
[26] Y. Mehta,et al. Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis , 2019, The New England journal of medicine.
[27] V. Najfeld,et al. Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative ACUTE Lymphoblastic Leukemia , 2018, Biology of Blood and Marrow Transplantation.
[28] A. Morris,et al. Decrease of Asparaginase Induced Thrombotic Events with Antithrombin III Monitoring and Repletion , 2018, Blood.
[29] L. Michaelis,et al. Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens , 2018, Blood.
[30] M. Minden,et al. Anticoagulation Prophylaxis with Weight-Adjusted Enoxaparin Reduces Rates of Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy , 2018, Blood.
[31] Shannon R. McCurdy,et al. Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice , 2018, Blood.
[32] F. Dentali,et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. , 2018, Blood advances.
[33] I. Aldoss,et al. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia , 2018, Leukemia & lymphoma.
[34] F. Berthold,et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents , 2018, Haematologica.
[35] H. Marquart,et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. , 2018, Blood.
[36] I. Aldoss,et al. A retrospective analysis of the impact of antithrombin III supplementation on the incidence of pegaspargase-induced venous thromboembolism. , 2018 .
[37] T. Klausen,et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia , 2018, Leukemia.
[38] R. Hough,et al. BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy , 2018, British journal of haematology.
[39] D. Neuberg,et al. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia , 2018, Journal of Thrombosis and Thrombolysis.
[40] Lara A. Kahale,et al. ضدانعقاد برای افراد مبتلا به سرطان و دارای کاتتر ورید مرکزی , 2018 .
[41] S. Goldberg,et al. Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) , 2017 .
[42] K. Schmiegelow,et al. Prolonged first‐line PEG‐asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol—Pharmacokinetics and antibody formation , 2017, Pediatric blood & cancer.
[43] Abstracts , 2017, Research and Practice in Thrombosis and Haemostasis.
[44] E. Jantunen,et al. A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients , 2017, Cancer medicine.
[45] W. Tissing,et al. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial , 2017, BMC Pediatrics.
[46] M. Patnaik,et al. Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy* , 2017, Leukemia & lymphoma.
[47] D. Rubens,et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. , 2017, Thrombosis research.
[48] H. Dombret,et al. Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study , 2016 .
[49] M. Minden,et al. Anticoagulation Prophylaxis in Asparaginase-Based Therapy in Adults with Acute Lymphoblastic Leukemia , 2016 .
[50] A. Rutjes,et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. , 2016, The Cochrane database of systematic reviews.
[51] M. Hernán,et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.
[52] M. Minden,et al. Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia. , 2016, Current oncology.
[53] L. Silverman,et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. , 2016, The Lancet. Oncology.
[54] R. Tait,et al. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events , 2016, Leukemia & lymphoma.
[55] M. Minden,et al. Safety of using escalated doses of enoxaparin prophylaxis in adults with acute lymphoblastic leukemia receiving asparaginase-based intensification therapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] A. Cheung,et al. Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis , 2016, Journal of General Internal Medicine.
[57] T. Klausen,et al. Toxicity profile and treatment delays in NOPHO ALL2008—comparing adults and children with Philadelphia chromosome‐negative acute lymphoblastic leukemia , 2016, European journal of haematology.
[58] C. Vetro,et al. Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study , 2016, Leukemia & lymphoma.
[59] Rachel Churchill,et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed , 2016, Journal of clinical epidemiology.
[60] H. Dombret,et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l‐asparaginase: The GRAALL experience , 2015, American journal of hematology.
[61] R. Tait,et al. Guideline on aspects of cancer‐related venous thrombosis , 2015, British journal of haematology.
[62] M. Millenson,et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[63] M. Minden,et al. Safety and feasibility of anticoagulation prophylaxis with enoxaparin in acute lymphoblastic leukemia during asparaginase-based intensification therapy. , 2015 .
[64] B. Dörken,et al. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] M. Luppi,et al. Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study , 2015, Leukemia & lymphoma.
[66] Gary H Lyman,et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] P. McFarlane,et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. , 2015, Current oncology.
[68] A. Khorana,et al. Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.
[69] Thomas Agoritsas,et al. Applying new strategies for the national adaptation, updating, and dissemination of trustworthy guidelines: results from the Norwegian adaptation of the Antithrombotic Therapy and the Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2014, Chest.
[70] B. Leber,et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia , 2014, Leukemia.
[71] A. Ferrajoli,et al. Incidence Rate Of Venous Thromboembolism (VTE) and Utilization Of a VTE Prophylaxis Order Set Module In Hospitalized Patients With Leukemia , 2013 .
[72] Lee-Wei Chen,et al. The Impact Of a Standardized Protocol On Thromboprophylaxis, Venous Thromboembolism and Bleeding Rates In Hospitalized Patients With Hematological Malignancies , 2013 .
[73] Lingyun Ji,et al. The Number Of Peg-Asparaginase Doses Administered Is a Determinant Of Relapse Risk In Adult ALL Treated With a Pediatric-Like Regimen , 2013 .
[74] L. Kremer,et al. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters. , 2013, The Cochrane database of systematic reviews.
[75] Andrea Cipriani,et al. Conceptual and Technical Challenges in Network Meta-analysis , 2013, Annals of Internal Medicine.
[76] A. Fielding,et al. The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia , 2013, Leukemia.
[77] B. van der Holt,et al. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation , 2013, Thrombosis and Haemostasis.
[78] A. Khorana,et al. Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis , 2012, Journal of thrombosis and haemostasis : JTH.
[79] C. Bennett,et al. Thromboprophylaxis Guidelines in Cancer with a Primary Focus on Ambulatory Patients Receiving Chemotherapy: A Review from the Southern Network on Adverse Reactions (SONAR) , 2012, Seminars in Thrombosis & Hemostasis.
[80] P. Preux,et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study , 2012, Cancer Chemotherapy and Pharmacology.
[81] A. Cohen,et al. How I manage venous thromboembolism risk in hospitalized medical patients. , 2012, Blood.
[82] Georgia Salanti,et al. Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool , 2012, Research synthesis methods.
[83] K. Schmiegelow,et al. Adult acute lymphoblastic leukaemia in Denmark. A national population‐based retrospective study on acute lymphoblastic leukaemia in Denmark 1998–2008 , 2012, British journal of haematology.
[84] A. Turpie,et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. , 2012, The New England journal of medicine.
[85] Elie A Akl,et al. Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .
[86] H. Liebman,et al. Treating venous thromboembolism in patients with cancer , 2012, Expert review of hematology.
[87] A. Bleyer,et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel , 2011, Leukemia & lymphoma.
[88] M. Mandalà,et al. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[89] J. Ioannidis,et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.
[90] Judy L. Smith,et al. Venous thromboembolic disease. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[91] D. Neuberg,et al. The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consortium protocols , 2011, British journal of haematology.
[92] Georgia Salanti,et al. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.
[93] H. van den Berg. Asparaginase revisited , 2011, Leukemia & lymphoma.
[94] E. Raetz,et al. Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia , 2010, Journal of pediatric hematology/oncology.
[95] D. Harats,et al. Conservative treatment of L‐asparaginase‐associated lipid abnormalities in children with acute lymphoblastic leukemia , 2010, Pediatric blood & cancer.
[96] M. De Cicco,et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[97] S. Barni,et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. , 2009, The Lancet. Oncology.
[98] H. Chew,et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. , 2009, Blood.
[99] Daniel W Rea,et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial , 2009, The Lancet.
[100] M. Frühwald,et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. , 2008, Blood.
[101] M. Bernard,et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study , 2008, Haematologica.
[102] C. Bloomfield,et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. , 2008, Blood.
[103] Georgia Salanti,et al. Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.
[104] A. Attarbaschi,et al. Fresh frozen plasma contains free asparagine and may replace the plasma asparagine pool during L-asparaginase therapy , 2008, Leukemia.
[105] Gary H Lyman,et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.
[106] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[107] M. Tormo,et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] Gary H Lyman,et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] H. Büller,et al. Prevention of catheter‐related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo‐controlled study , 2007, Journal of thrombosis and haemostasis : JTH.
[110] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[111] A. Castelnuovo,et al. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta‐analysis , 2007, Journal of thrombosis and haemostasis : JTH.
[112] S. Richards,et al. Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials , 2007, Pediatric blood & cancer.
[113] J. Douketis,et al. Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients , 2007, Annals of Internal Medicine.
[114] John Wu,et al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with l‐asparaginase: an in vitro study , 2006, British journal of haematology.
[115] G. Steger,et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[116] P. Chiusolo,et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment , 2005, Journal of thrombosis and haemostasis : JTH.
[117] A. Santoro,et al. Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: analysis of its use in 427 cancer patients. , 2005, Anticancer research.
[118] Armando Santoro,et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] D. Anderson,et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[121] P. Sonneveld,et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands , 2004, Leukemia.
[122] M. Bernard,et al. Evolution of Antithrombin (AT) and Fibrinogen (Fg) Levels during Induction Chemotherapy with L-Asparaginase (Asp) in Adult Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL). Clinical Outcomes and Use of Coagulation Supportive Treatments: The CAPELAL Study. , 2004 .
[123] J. Heit,et al. Thromboembolism in Adults with Acute Lymphoblastic Leukemia During Induction with L-Asparaginase-containing Multi-agent Regimens: Incidence, Risk Factors, and Possible Role of Antithrombin , 2004, Leukemia & lymphoma.
[124] T. Ben Othman,et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease , 2004, Thrombosis and Haemostasis.
[125] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[126] K. Bauer. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. , 2003, Chest.
[127] J. Cayuela,et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[128] D. Heaton,et al. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis , 2002, Internal medicine journal.
[129] T. Robak,et al. The Influence of Low Molecular Weight Heparin on the Intravascular Activation of the Coagulation System in Patients With Acute Leukemia During Induction Chemotherapy--Report of a Prospective Randomized Study , 2002, Leukemia & lymphoma.
[130] R. Junker,et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. , 2001, Thrombosis research.
[131] S. Olson,et al. Heparin Enhances the Specificity of Antithrombin for Thrombin and Factor Xa Independent of the Reactive Center Loop Sequence , 2001, The Journal of Biological Chemistry.
[132] R. Gelber,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.
[133] M. Davidson,et al. Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. , 1999, Clinical and laboratory haematology.
[134] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[135] R. Marcus,et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies , 1998, British journal of haematology.
[136] R. Rosell,et al. Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin) , 1996, Thrombosis and Haemostasis.
[137] F. Mandelli,et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli-asparaginase. A Gimema study , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[138] A. Giles,et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. , 1994, Blood.
[139] F. Mandelli,et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L‐asparaginase during induction therapy: A retrospective study , 1992, European journal of haematology.
[140] L. Mottola,et al. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase. , 1991, Haematologica.
[141] S. Tura,et al. Hypercoagulability during l‐asparaginase treatment: the effect of antithrombin III supplementation in vivo , 1990, British journal of haematology.
[142] P. Benotti,et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.
[143] I. Björk,et al. Mechanism of the anticoagulant action of heparin , 1982, Molecular and Cellular Biochemistry.
[144] P. Mintz,et al. Antithrombin III in Fresh Frozen Plasma, Cryoprecipitate, and Cryoprecipitate‐depleted Plasma , 1979, Transfusion.
[145] C. Bloomfield,et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia , 2013, Cancer.
[146] D. Moher,et al. Chapter 10: Addressing reporting biases , 2011 .
[147] K. Bauer,et al. New Anticoagulants , 2007, Hematology. American Society of Hematology. Education Program.
[148] U. Jäger,et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. , 2005, Thrombosis research.
[149] Anthony K. C. Chan,et al. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. , 2003, Thrombosis research.
[150] John Wu,et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia , 2003, Thrombosis and Haemostasis.
[151] S. Laporte,et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. , 2003, Haematologica.
[152] E. Pogliani,et al. L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy. , 1995, Acta haematologica.
[153] C. Esmon,et al. Anticoagulation proteins C and S. , 1987, Advances in experimental medicine and biology.